ARTES Biotechnology and Basic Pharma join in a strategic Collaboration and Co Marketing Partnership for Pharmaceutical Recombinant Protein Production

ARTES Biotechnology, a leading company specializing in development and transfer of recombinant cell lines and protein production processes from microbial expression systems and our member Basic Pharma, a pharmaceutical company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation.
Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards. The overarching objective of this alliance is to establish a streamlined s upply chain process that expedites time to market for new pharmaceutical products.

ARTES Biotechnology’s Managing Director, Michael Piontek, remarked, “This alliance marks the first step in realizing our new strategy offering research reagents for non-human applications. Together with Basic Pharma, today we start with Human Serum Albumin produced from our proprietary yeast Hansenula. Tomorrow, we will expand this portfolio with further enzymes, antigens and functional proteins.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his enthusiasm for the collaboration: “We are delighted to join forces with ARTES Biotechnology on this venture. The synergy between ARTES Biotechnology’s proficiency in recombinant cell line development and our experience in pharmaceutical development is a perfect match.” Bob Kool, Managing director at Basic Pharma further emphasized: “We are excited to embark on this strategic journey alongside ARTES Biotechnology. The fusion of our pharmaceutical development experience with their cutting-edge protein production expertise promises a dynamic partnership.”

LifetecZONe is one of the seven projectpartners that collaborate within Eurocluster BioMan4R2 and rolled out a financial support scheme.  We are proud that cluster member Basic Pharma has been awarded financial support and that we have been able to contribute to further strengthening the South Netherlands ecosystem. 

Delen:
× App LifetecZONe
Ga naar de inhoud